Skip to main content
Have a personal or library account? Click to login
Early- and Late-Onset Inherited Erythromelalgia Cover

Early- and Late-Onset Inherited Erythromelalgia

Open Access
|Aug 2009

Full Article

A genotype-phenotype relationship at the clinical, cellular and molecular levels is shown in a case of erythromelalgia of relatively late onset, in a study at Yale University School of Medicine, and centers in China. The patient, a male age 17 years, began experiencing excruciating pain, warmth and redness in both feet and lower legs at age 14 years. Blood was analyzed for mutations in SCN9A, gain-of-function sodium channel mutations that are preferentially expressed within dorsal root ganglia (DRG) and sympathetic ganglion neurons. The effect of the Q10R mutation on firing of DRG neurons was investigated by current-clamp recording. The hyperexcitability of the DRG neuron induced by Q10R mutation in this adolescent patient was smaller than the change produced by I848T, an early-onset erythromelalgia mutation. [1]

COMMENT. Inherited erythromelalgia (erythermalgia) (IEM) is an autosomal dominant disorder characterized by severe burning pain and erythema of the extremities triggered by warmth. IEM is linked to gain-of-function mutations in SCN9A, the gene encoding Na, 1.7, a voltage-gated sodium channel that is preferentially expressed in dorsal root ganglion neurons, particularly nociceptors, and sympathetic ganglion neurons. The resultant nociceptor hyperexcitability causes pain in the extremities. Almost all cases reported are linked to families with onset in early childhood (infancy to 6 years of age). The above case report uncovers a new mutation in Na, 1.7, Q10R, from a patient with onset in the second decade of life. Mutations that produce smaller effects on sodium channel activation are associated with a smaller degree of DRG neuron excitability and later onset of clinical signs.

Carbamazepine-responsive erythromelalgia and Nav1.7 mutation. The above team of investigators publish a second article on erythromelalgia [2], reporting a novel Nav1.7 mutation (V400M) in a three-generation Canadian family with pain relieved by carbamazepine (CBZ). Nav1.7 sodium channels are preferentially expressed within nociceptor ganglia and sympathetic neurons that are involved in the inflammatory and neuropathic pain of inherited erythromelalgia. CBZ has a normalizing effect on mutant Nav1.7 channels in this Canadian kindred, preventing the hyperexcitability of dorsal root ganglia in erythromelalgia.

Language: English
Page range: 63 - 63
Published on: Aug 1, 2009
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services

© 2009 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.